.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,435,427

« Back to Dashboard

Claims for Patent: 7,435,427

Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s): Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Philippe (Uccle, BE)
Assignee: Galephar M/F (Marche-en-Famenne, BG)
Application Number:10/380,619
Patent Claims: 1. An oral pharmaceutical composition of isotretinoin contained in a pharmaceutically acceptable capsule which comprises a semi-solid suspension containing at least two lipidic excipients, at least in an amount of about 20 to 80% of one being hydrophilic having a HLB value equal to or greater than 10 selected from the group consisting of glyceroyl macrogolglycerides, polyethylene glycol esters, and mixtures thereof; the other in an amount of about 5 to 70% and being an oily vehicle selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, glycerol oleate and mixtures thereof; and an amount of about 1 to 10% of at least one additional surfactant.

2. The pharmaceutical composition of claim 1, wherein the least one hydrophilic lipidic excipient has an HLB value of at least 12.

3. The pharmaceutical composition of claim 1, wherein the least one hydrophilic lipidic excipient has an HLB value of at least 13.

4. The pharmaceutical composition of claim 1, wherein the at least one additional surfactant is selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acid esters, sodium laurylsulfate, lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, polyethylene glycol and mixtures thereof.

5. The pharmaceutical composition of claim 1, which further comprises at least one disintegrant.

6. The pharmaceutical composition of claim 5, wherein at least one disintegrant is selected from the group consisting povidone, sodium croscarmellose and mixtures thereof.

7. The capsule of claim 1, in which the pharmaceutically-acceptable capsule is selected from the group consisting of hard gelatin capsules, soft gelatin capsules, hypromellose capsules, and starch capsules.

8. The pharmaceutical composition of claim 1, wherein the composition comprises about 10-20 mg of isotretinoin.

9. The pharmaceutical composition of claim 8, wherein the composition comprises about 16-20 mg of isotretinoin.

10. A method of administering the pharmaceutical composition of claim 1, which comprises administering to a human about 10-20 mg of the composition for a total daily dose.

11. The method of claim 10, wherein the total daily dose is about 16-20 mg.

12. The pharmaceutical composition of claim 1, wherein the composition contains about 20-80% by weight of glyceroyl macrogolglycerides, about 5-70% by weight of an oily vehicle and about 1-10% of an additional surfactant.

13. The oral pharmaceutical composition of claim 1, wherein the pharmaceutically-acceptable capsule is filled by a process comprising filling into a capsule a composition prepared by mixing isotretinoin and one or more of the pre-melted lipidic excipients.

14. The oral pharmaceutical composition of claim 1, wherein the pharmaceutically-acceptable capsule is filled by a process comprising filling into a capsule a composition prepared by mixing: (a) isotretinoin, (b) one or more of said hydrophilic lipidic excipients, (c) said oily vehicle, and (d) one or more additional ingredients selected from the group consisting of disintegrants, surfactants and combinations thereof.

15. The pharmaceutical composition of claim 1, wherein the hydrophilic lipidic excipients further comprise an excipient having an HLB value of at least 12, and the oily vehicle is soybean oil.

16. The pharmaceutical composition of claim 1, wherein the isotretinoin is contained within an emulsion.

17. The pharmaceutical composition of claim 1, wherein the at least one hydrophilic lipidic excipient having an HLB value equal to or greater than 10 is glycerol macrogolglycerides.

18. The pharmaceutical composition of claim 1, wherein the oily vehicle is a medium chain triglycerides or a mixture of medium chain triglycerides.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc